We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Expands Agreement with GlaxoSmithKline to Develop Companion Diagnostic

By LabMedica International staff writers
Posted on 15 Dec 2011
Print article
Abbott (Abbott Park, IL, USA) will expand its existing agreement with GlaxoSmithKline Biologicals (GSK; Brentford, United Kingdom) to include the development of an additional companion diagnostic test for a cancer immunotherapy antigen.

The existing agreements between the two companies focused on the development of PCR tests to screen non-small-cell lung cancer and melanoma tumors for expression of the MAGE-A3 antigen. MAGE-A3 is a tumor-specific antigen that is expressed in a large variety of cancers, including melanoma, non-small-cell lung, head and neck, and bladder cancer, with no expression in normal cells. Expression of the MAGE-A3 gene has been observed in testicular cells but without antigen presentation capabilities.

Under the expanded agreement, Abbott will develop a polymerase chain reaction (PCR) test for use on the Abbott m2000rt instrument to screen non-small-cell lung cancer tumors for expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69 % of non-small-cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

Abbott is a pioneer in the use of molecular tests based on PCR and fluorescence in situ hybridization (FISH) technologies to aid clinicians in the selection of appropriate pharmacogenomic therapies.

GSK’s Antigen Specific Cancer Immunotherapy Program (ASCI) is investigated in the clinic to support their use to reduce the risk of tumor recurrence following surgery, or to impact tumor growth in an early metastatic setting. The highly specific mode of action of GSK’s ASCIs allows development of diagnostic tools to aid in selecting patients eligible for the treatment, depending on the expression of the tumor antigens.

Related Links:

Abbott
GlaxoSmithKline Biologicals


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more